Clinical Trial

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Name: Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer — clinical trial record (NCT03526432)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a single arm, Phase II study using the combination of atezolizumab and bevicacizumab in women with advanced, recurrent or persistent endometrial cancer. Safety and futility of this drug combination will be assessed to see what effect this treatment has on this patient population.

Trial Details

NCT Number	NCT03526432
Lead Sponsor	University of Oklahoma Collaborators: Genentech, Inc.
Conditions	Endometrial Cancer
Enrollment	110 participants
Start Date	2018-08-08
Primary Completion	2026-06-30 (estimated)
Study Completion	2026-09 (estimated)
Updated on ClinicalTrials.gov	2026-06-05